RedHill Biopharma Ltd. (RDHL) Form 6-K — Oct 13, 2026
RedHill Biopharma filed a 6-K announcing a prospectus supplement dated October 13, 2026 that increases the maximum aggregate offering amount of ADSs issuable under its At The Market Offering Agreement with H.C. Wainwright. Each ADS represents 10,000 ordinary shares, and the increased capacity is up to $2,587,409, sold from time to time under the February 3, 2025 ATM agreement.
Key figures
- Ads ratio
- 1 ADS = 10,000 ordinary shares
- Atm agreement date
- 2025-02-03
- Atm increase amount
- 2587409
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.